<DOC>
	<DOCNO>NCT00399711</DOCNO>
	<brief_summary>This trial conduct United States America ( USA ) . This trial compare change HbA1c 26 week repaglinide metformin fix dose combination tablet give twice daily versus three time daily regimen versus twice daily rosiglitazone metformin fix dose combination tablet subject type 2 diabetes currently monotherapy .</brief_summary>
	<brief_title>Effect Repaglinide Metformin Combination Tablet Rosiglitazone Metformin Fixed Dose Combination Blood Glucose Control Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<mesh_term>Repaglinide</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Type 2 diabetes least 3 month HbA1c 7.511.0 % monotherapy HbA1c 7.010.0 % dual therapy BMI maximum 45 kg/m2 Any clinically significant disease history opinion investigator Severe heart disease Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>